PITTSBURGH, Pa. - The generic drugmaker Mylan is buying Abbott Laboratories' generic-drugs business in developed markets for stock valued at about $5.3 billion. Mylan said Monday that the deal will diversify and expand its business …
Netherlands-based Mylan said it also intends to continue to market and distribute branded EpiPen. Mylan's shares were up about 1 percent at $43.53 in premarket trading. The stock had fallen 12 percent last week.
Shares of Mylan N.V. MYL have declined 24.7% in the last six months compared to the industry’s loss of 20.0%. Here we analyze the factors that led to the underperformance. Mylan is a global pharmaceutical company with a well …
The Teva cash and stock proposal provides Mylan stockholders with a substantial premium and immediate cash value, as well as significant potential for future value creation through participation in a financially and commercially stronger …
RadioShack (NYSE: RSH) 35.5% HIGHER; is said to have reached an agreement with a consortium led by Standard General with respect to a $590 million financing agreement. Durata Therapeutics (NASDAQ: DRTX) 10% HIGHER; …
NEW YORK: Mylan N.V. rejected Teva Pharmaceuticals' $40.1 billion buyout offer, saying the cash-and-stock proposal undervalues the company. Mylan said that it won't think about starting talks unless Teva offers more than $100 per …
NEW YORK — Teva has offered to buy Mylan in a cash-and-stock deal valued at about $40.1 billion. The potential combination would result in a powerhouse of a generic drug developer competing against rivals such as Sun Pharma. …
Carmignac Gestion SA, which had managed several French mutual funds that purchased Perrigo stock, accused Perrigo and its executives of falsely claiming that the company could weather generic drug pricing pressures, that it forecasted …
Netherlands-based Mylan said it also intends to continue to market and distribute branded EpiPen. Mylan's shares were up about 1 percent at $43.53 in premarket trading. The stock had fallen 12 percent last week.